The Innovative Medicines Initiative (IMI) has launched IMI2 – Call 13.
Stage 1 submission deadline: 28 February 2018
Stage 2 submission deadline: 06 September 2018
Proposals must be submitted via the electronic submission system of the Horizon 2020 Participant Portal.
Detailed information: https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/calls/h2020-jti-imi2-2017-13-two-stage.html
If you want to apply to take part in a new IMI project, you need to find or build an applicant consortium, and to do this, you will need to find partners.
https://www.imi.europa.eu/content/partner-search page provides some tips on how to go about this.
Open call topics:
• IMI2-2017-13-01: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
• IMI2-2017-13-02: Genome-Environment Interactions in Inflammatory Skin Disease
• IMI2-2017-13-03: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
• IMI2-2017-13-04: Mitochondrial Dysfunction in Neurodegeneration
• IMI2-2017-13-05: Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative
• IMI2-2017-13-06: A sustainable European induced pluripotent stem cell platform
• IMI2-2017-13-07: Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
• IMI2-2017-13-08: Human Tumour Microenvironment Immunoprofiling
• IMI2-2017-13-09: ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now
• IMI2-2017-13-10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
• IMI2-2017-13-11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
• IMI2-2017-13-12: Pilot programme on a Clinical Compound Bank for Repurposing: Cardiovascular diseases and diabetes
• IMI2-2017-13-13: Pilot programme on a Clinical Compound Bank for Repurposing: Respiratory diseases
• IMI2-2017-13-14: Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases
• IMI2-2017-13-15: Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases